Welcome to our dedicated page for ELUTIA SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Elutia Inc. (ELUT) completed the sale of its SimpliDerm human acellular dermis business, which comprised substantially all assets of its Women’s Health segment, to Cellution Biologics Inc. on August 17, 2026. Elutia received $7.7 million of net cash proceeds at closing, subject to post‑closing inventory adjustments, and may receive up to an additional $3.0 million in contingent milestone payments over 18 months. A company press release describes total consideration of up to $11 million, including $8 million at closing before transaction expenses and adjustments. The sale is treated as a divestiture of a business and will be reported as a discontinued operation beginning with the quarter ended September 30, 2026, with detailed unaudited pro forma financials provided. Elutia also entered a five‑year non‑competition agreement in hADM lines, a transition services agreement of up to six months, and amended its Loan and Security Agreement to release the lien on the sold assets. Management states that the transaction strengthens the balance sheet with non‑dilutive capital and allows strategic focus on the NXT‑41x drug‑eluting biomatrix program.
Elutia Inc. reports continued operating losses as it transitions to a focused drug‑eluting biomatrix business following prior divestitures of its Orthobiologics and CIED segments. For the six months ended June 30, 2026, net sales from continuing operations were $5.5 million, with a net loss from continuing operations of $15.5 million.
Gross profit improved year over year, but higher research and development spending on next‑generation products NXT‑41 and NXT‑41x, along with ongoing litigation costs, kept total operating expenses at $17.6 million. Operating cash outflow was $16.3 million, leaving cash and cash equivalents of $19.9 million and total assets of $43.6 million at June 30, 2026.
The company carries a current revenue interest obligation of $6.4 million and a contingent legal liability of $5.6 million related mainly to FiberCel and VBM product litigation, partially offset by $3.9 million in insurance receivables. Elutia also discloses a Nasdaq notice received on August 6, 2026 that its share price has traded below the $1.00 minimum bid, triggering a 180‑day compliance period.
SilverArc Capital Management, LLC and Devesh Gandhi report their beneficial ownership of 2,192,980 shares of Elutia Inc. Class A common stock on an amended Schedule 13G. This position represents 4.9% of the class, reported as beneficially owned by each of the reporting persons.
Both SilverArc and Gandhi report no sole voting or dispositive power over Elutia shares, and instead disclose shared voting and shared dispositive power over 2,192,980 shares. The filing characterizes their holdings as ownership of 5 percent or less of the class.
Elutia Inc. reported second quarter 2026 results and outlined funding and regulatory milestones for its NXT-41 and NXT-41x drug-eluting biomatrix programs. The company has secured up to $26 million of additional capital intended to fund operations through anticipated FDA clearance of NXT-41x and its first full commercial launch year in 2028, without an equity offering, and expects release of the remaining $8 million BioEnvelope escrow in the fourth quarter of 2026.
Elutia signed a definitive agreement to sell its SimpliDerm business for up to $11 million, including up to $3 million in contingent payments over 18 months after closing, and continues a strategic process for its Cardiovascular business. For the quarter ended June 30, 2026, net sales from continuing operations were $2.4 million versus $2.7 million a year earlier, with a net loss of $7.6 million versus $9.6 million. Gross margin improved to 59.6%, with non-GAAP adjusted gross margin of 70.7%. Cash and cash equivalents were $19.9 million at June 30, 2026, down from $36.4 million at December 31, 2025, and the accumulated deficit was $191.3 million.
Elutia Inc. has a significant shareholder group reported by SilverArc Capital Management, LLC and Devesh Gandhi. The reporting persons state that they beneficially own 2,192,980 shares of Elutia Class A common stock, representing 4.9% of the class as of June 30, 2026.
The filing states they have shared voting and dispositive power over all 2,192,980 shares, with no sole voting or dispositive power. The ownership is explicitly described as 5 percent or less of the class, and both reporting persons are identified jointly as the filing parties.
Elutia Inc. reported that on August 6, 2026 it received a notice from Nasdaq that the closing bid price of its Class A common stock had been below the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market for the last 30 consecutive business days, creating a deficiency under Nasdaq Listing Rule 5550(a)(2).
The shares continue to trade under the symbol ELUT while Elutia has 180 calendar days, until February 2, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for at least ten consecutive business days, subject to possible Nasdaq staff discretion.
If compliance is not regained in this period, Elutia may qualify for an additional 180-day extension if it satisfies other initial listing standards and indicates it may cure the deficiency, potentially including a reverse stock split. Elutia states it intends to monitor its share price and evaluate options but cautions there is no assurance it will regain or maintain Nasdaq listing compliance.
Elutia Inc. signed an Asset Purchase Agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for up to $11 million. Consideration includes a base purchase price of $8 million in cash at closing, up to $2 million tied to technology transfer and manufacturing transition milestones over 18 months, and up to $1 million in earn-out payments based on SimpliDerm sales exceeding specified quarterly revenue targets.
The sale covers substantially all assets of Elutia’s Women’s Health segment, with Cellution Biologics assuming only certain contract-related liabilities. Elutia agreed to five-year non-competition and non-solicitation covenants in human acellular dermis products and will provide transition services after closing. Closing is expected in the second half of 2026, subject to customary conditions and an outside date of January 16, 2027. According to management, proceeds are intended to strengthen the balance sheet without equity dilution and support the planned 2027 commercial launch of NXT-41x.
ELUTIA INC. President and CEO C. Randal Mills reported compensation-related equity activity involving restricted stock units that vested into Class A Common Stock. On this vesting, 22,473 shares were issued upon conversion of restricted stock units, and 8,064 of those shares were withheld by the company to cover tax obligations. These transactions were recorded as an option-style exercise and a tax-withholding disposition rather than open-market buying or selling. After the transactions, Mills directly held 441,180 shares of Class A Common Stock, indicating he retained most of the newly vested shares as ongoing equity exposure.
Elutia Inc. reported results of its 2026 annual stockholder meeting and an approved change to its long-term incentive plan. Stockholders approved a First Amendment to the Amended and Restated 2020 Incentive Award Plan, adding authorization for an additional 3,000,000 shares of Class A common stock for awards, extending the plan’s annual share increase feature through January 1, 2036 and moving the plan termination date to the tenth anniversary of the April 22, 2026 amendment date.
All other proposals passed, including election of two Class III directors to terms ending in 2029, ratification of PricewaterhouseCoopers LLP as auditor for 2026, and advisory approval of executive compensation. Stockholders also advised holding future say-on-pay votes every year, and the board chose an annual frequency accordingly.
Elutia Inc. director and ten percent owner Kevin Rakin reported receiving a grant of stock options covering 159,590 shares of Class A Common Stock at an exercise price of $0.96 per share. The options vest on the earlier of the day before the first annual meeting after grant or the first anniversary, subject to his continued board service, and expire on June 11, 2036. Following this award, he holds 159,590 derivative securities directly.